Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Synthetic Nucleic Acids Restore Normal Frataxin Levels in Patient-Derived Friedreich's Ataxia Cells

By LabMedica International staff writers
Posted on 02 Mar 2016
Neurological disease researchers have used synthetic nucleic acid polymers to block the defective FXN gene segment and restore normal levels of frataxin in cells derived from patients with Freidreich's ataxia.

Friedreich's ataxia is an autosomal recessive disorder that occurs when the FXN gene contains amplified repeats of the GAA (guanine-adenine-adenine) nucleotide sequence. More...
The FXN gene encodes the protein frataxin, but GAA repeat expansion causes frataxin levels to be reduced. Frataxin is an iron-binding protein responsible for forming iron-sulfur clusters. One result of frataxin deficiency is mitochondrial iron overload which can cause damage to many proteins, which can result in a variety of symptoms that include loss of muscle control, fatigue, vision or hearing impairment, slurred speech, and serious heart conditions.

Investigators at the University of Texas Southwestern Medical Center (Dallas, USA) developed synthetic nucleic acids to block the effects of GAA expansion and restore normal frataxin levels.

In a paper published in the February 4, 2016, online edition of the journal Nature Communications the investigators reported that by introducing anti-GAA duplex RNAs or single-stranded locked nucleic acids into patient-derived cells, they were able to increase frataxin expression to levels similar to analogous wild-type cells. These results were considered to be significant, since synthetic nucleic acids that target GAA repeats could lead to the development of compounds for restoring curative frataxin levels. More broadly, they demonstrated a new strategy for upregulating gene expression.

"The problem arises because of a mutation within the frataxin gene (FXN) that does not code for protein. In this case, the mutation causes the synthesis of a longer piece of RNA. This longer sequence binds the DNA and gums up the works, blocking RNA production needed to produce the frataxin protein," said senior author Dr. David Corey, professor of pharmacology and biochemistry at the University of Texas Southwestern Medical Center. "The synthetic DNA or RNA prevents the mutant sequence from bending back and blocking the frataxin gene. This action activates the frataxin gene, which then makes frataxin RNA and protein at normal levels. In addition, our approach is selective for targeting the frataxin gene FXN and does not affect other genes."

Related Links:

University of Texas Southwestern Medical Center



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.